Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis

Background Atopic dermatitis is a chronic relapsing inflammatory skin condition. One of the most common skin disorders in children, atopic dermatitis typically manifests before the age of 5 years, but it can develop at any age. Atopic dermatitis is characterised by dry, inflamed skin accompanied by...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Steven J Edwards, Charlotta Karner, Tracey Jhita, Samantha Barton, Gemma Marceniuk, Zenas Z N Yiu, Miriam Wittmann
Format:	Artigo
Sprog:	Inglês
Udgivet:	NIHR Journals Library 2024-01-01
Serier:	Health Technology Assessment
Fag:	atopic dermatitis abrocitinibatopic dermatitis tralokinumab upadacitinib cost effectivenesssystematic review cost effectivenesstralokinumab
Online adgang:	https://doi.org/10.3310/LEXB9006
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!